RLYB - Rallybio Corp
IEX Last Trade
0.9201
0.030 3.217%
Share volume: 456
Last Updated: Thu 26 Dec 2024 08:15:47 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.89
0.03
3.32%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-5.95%
1 Month
-20.64%
3 Months
-22.78%
6 Months
-38.78%
1 Year
-67.41%
2 Year
-85.09%
Key data
Stock price
$0.92
DAY RANGE
$0.87 - $0.90
52 WEEK RANGE
$0.91 - $2.77
52 WEEK CHANGE
-$65.72
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Martin W. MacKay
Region: US
Website: rallybio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: rallybio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)
Recent news